Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 121

Related Citations for PubMed (Select 21931374)

1.

Management of the metabolic effects of HIV and HIV drugs.

Brown TT, Glesby MJ.

Nat Rev Endocrinol. 2011 Sep 20;8(1):11-21. doi: 10.1038/nrendo.2011.151. Review.

2.

Human immunodeficiency virus and highly active antiretroviral therapy-associated metabolic disorders and risk factors for cardiovascular disease.

Anuurad E, Semrad A, Berglund L.

Metab Syndr Relat Disord. 2009 Oct;7(5):401-10. doi: 10.1089/met.2008.0096. Review.

3.
4.

Lipodystrophy and metabolic abnormalities in Slovenian HIV-infected patients.

Tomazic J, Silic A, Karner P, Vidmar L, Maticic M, Poljak M, Ihan A, Janez A.

Wien Klin Wochenschr. 2004 Nov 30;116(21-22):755-9.

PMID:
15628647
5.

[Lipid disorders in patients with HIV-induced diseases].

Chanu B, Valensi P.

Presse Med. 2005 Sep 10;34(15):1087-94. Review. French.

PMID:
16334888
6.
7.

[Metabolic disturbances associated with HAART].

Olczak A.

Przegl Epidemiol. 2007;61(4):639-46. Review. Polish.

PMID:
18572495
8.

Lipotoxicity on the basis of metabolic syndrome and lipodystrophy in HIV-1-infected patients under antiretroviral treatment.

Giralt M, Díaz-Delfín J, Gallego-Escuredo JM, Villarroya J, Domingo P, Villarroya F.

Curr Pharm Des. 2010 Oct;16(30):3371-8. Review.

PMID:
20687888
9.

Lipodystrophy and metabolic disorders in HIV-1-infected adults on 4- to 9-year antiretroviral therapy in Senegal: a case-control study.

Mercier S, Gueye NF, Cournil A, Fontbonne A, Copin N, Ndiaye I, Dupuy AM, Cames C, Sow PS, Ndoye I, Delaporte E, Simondon KB.

J Acquir Immune Defic Syndr. 2009 Jun 1;51(2):224-30. doi: 10.1097/QAI.0b013e31819c16f4.

PMID:
19339897
10.

Toxic metabolic syndrome associated with HAART.

Haugaard SB.

Expert Opin Drug Metab Toxicol. 2006 Jun;2(3):429-45. Review.

PMID:
16863444
11.

Highly active antiretroviral therapy and cardiovascular complications in HIV-infected patients.

Barbaro G, Klatt EC.

Curr Pharm Des. 2003;9(18):1475-81. Review.

PMID:
12769727
12.

HIV and increased risk of cardiovascular diseases.

Das S.

Sex Health. 2005;2(4):219-21. Review.

PMID:
16402668
13.

[Lipodystrophy and lipid metabolism alterations in HIV-infected patients receiving highly active antiretroviral therapy (HAART)].

Calza L, Manfredi R, Chiodo F.

Recenti Prog Med. 2004 May;95(5):265-75. Review. Italian.

PMID:
15202680
14.

Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management.

Gutierrez AD, Balasubramanyam A.

Endocrine. 2012 Feb;41(1):1-10. doi: 10.1007/s12020-011-9565-z. Epub 2011 Dec 2. Review.

15.
16.

Metabolic disorders and cardiovascular risk in HIV-infected patients treated with antiretroviral agents.

Fantoni M, Del Borgo C, Autore C, Barbaro G.

Ital Heart J. 2002 May;3(5):294-9. Review.

PMID:
12066561
17.

Metabolic complications of antiretroviral therapy in children.

Leonard EG, McComsey GA.

Pediatr Infect Dis J. 2003 Jan;22(1):77-84. Review.

PMID:
12544413
18.

The metabolic syndrome, an epidemic among HIV-infected patients on HAART.

Jevtović DJ, Dragović G, Salemović D, Ranin J, Djurković-Djaković O.

Biomed Pharmacother. 2009 Jun;63(5):337-42. doi: 10.1016/j.biopha.2008.09.011. Epub 2008 Oct 23.

PMID:
18996676
19.

Management of metabolic complications and cardiovascular risk in HIV-infected patients.

Blanco F, San Román J, Vispo E, López M, Salto A, Abad V, Soriano V.

AIDS Rev. 2010 Oct-Dec;12(4):231-41. Review.

PMID:
21179187
20.

[Metabolic abnormalities in patients with HIV infection].

Rodríguez-Carranza SI, Aguilar-Salinas CA.

Rev Invest Clin. 2004 Mar-Apr;56(2):193-208. Review. Spanish.

PMID:
15377073
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk